Abstract
Considerable research has been devoted to the role of the adaptive immune system in the pathogenesis of autoimmune inflammatory demyelination (AID). AID is thought to occur spontaneously in patients with multiple sclerosis (MS), a common cause of neurological disability. AID is also observed in the best characterized animal model of MS, experimental autoimmune encephalomyelitis (EAE). The adaptive immune system recognizes and responds to antigens via highly specific T-cell receptors. Myelin-reactive T-cells may initiate pathological immune responses that lead to central nervous system damage in MS and EAE. By contrast, the innate immune system recognizes evolutionarily conserved structures that are common to invading pathogens with high efficiency for rapid recognition and elimination of viruses, bacteria, and fungi. This recognition is mediated by pattern-recognition receptors such as Toll-like receptors (TLRs) expressed on cells of the innate immune system (dendritic cells and CNS-resident cells, such as microglia) that have the potential to activate autoimmune responses by inducing the production of inflammatory cytokines and chemokines. Conversely, the innate immune system can also regulate autoimmune inflammation by inducing the production of immunoregulatory molecules such as type I interferons, which are currently used in the treatment of MS. We review the evidence that TLRs can exacerbate or regulate AID and discuss the therapeutic potential of targeting either process.
Keywords: MS/EAE, autoimmune disease, Toll-like receptor
Current Medicinal Chemistry
Title: Role of the Innate Immune System in Autoimmune Inflammatory Demyelination
Volume: 15 Issue: 11
Author(s): Kate O'Brien, Denise C. Fitzgerald, Karmeswaree Naiken, Kishore R. Alugupalli, A. M. Rostami and Bruno Gran
Affiliation:
Keywords: MS/EAE, autoimmune disease, Toll-like receptor
Abstract: Considerable research has been devoted to the role of the adaptive immune system in the pathogenesis of autoimmune inflammatory demyelination (AID). AID is thought to occur spontaneously in patients with multiple sclerosis (MS), a common cause of neurological disability. AID is also observed in the best characterized animal model of MS, experimental autoimmune encephalomyelitis (EAE). The adaptive immune system recognizes and responds to antigens via highly specific T-cell receptors. Myelin-reactive T-cells may initiate pathological immune responses that lead to central nervous system damage in MS and EAE. By contrast, the innate immune system recognizes evolutionarily conserved structures that are common to invading pathogens with high efficiency for rapid recognition and elimination of viruses, bacteria, and fungi. This recognition is mediated by pattern-recognition receptors such as Toll-like receptors (TLRs) expressed on cells of the innate immune system (dendritic cells and CNS-resident cells, such as microglia) that have the potential to activate autoimmune responses by inducing the production of inflammatory cytokines and chemokines. Conversely, the innate immune system can also regulate autoimmune inflammation by inducing the production of immunoregulatory molecules such as type I interferons, which are currently used in the treatment of MS. We review the evidence that TLRs can exacerbate or regulate AID and discuss the therapeutic potential of targeting either process.
Export Options
About this article
Cite this article as:
O'Brien Kate, Fitzgerald C. Denise, Naiken Karmeswaree, Alugupalli R. Kishore, Rostami M. A. and Gran Bruno, Role of the Innate Immune System in Autoimmune Inflammatory Demyelination, Current Medicinal Chemistry 2008; 15 (11) . https://dx.doi.org/10.2174/092986708784221458
DOI https://dx.doi.org/10.2174/092986708784221458 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Current Molecular Medicine Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research Vitamin D: Status, Supplementation and Immunomodulation
Current Nutrition & Food Science Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design The Monocyte Locomotion Inhibitory Factor an Anti-Inflammatory Peptide; Therapeutics Originating from Amebic Abscess of the Liver
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology